✦ LIBER ✦

A National Cancer Institute of Canada Clinical Trials Group Study – IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer

✍ Scribed by J.A. Maroun; D. Jonker; L. Seymour; R. Goel; M. Vincent; W. Kocha; C. Cripps; B. Fisher; D. Lister; A. Malpage; G. Chiritescu

Book ID: 116428743
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 131 KB
Volume: 42
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2005.08.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of triple drug combination

Phase I study of triple drug combination of CPT-11 (C), Oxaliplatin (O) and Tomudex (T) (COT) in previously untreated metastatic colorectal cancer (MCRC): National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), IND.135

✍ Maroun, J.A.; Jonker, D.; Seymour, L.; Goel, R.; Kocha, W.; Fisher, B. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 206 KB

Phase II study of flutamide in patients

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

✍ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.

A phase II trial of zd0473 in patients w

A phase II trial of zd0473 in patients with metastatic breast cancer. A National Cancer Institute of Canada clinical trials group study (NCIC CTG-IND 129)

✍ T.A. Vandenberg; K.A. Gelmon; L. Panasci; M. Crump; B. Norris; A. Tomiak; T. She 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 166 KB

A phase I study of T900607 given once ev

A phase I study of T900607 given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 130)

✍ K.A. Gelmon; K. Belanger; C. Britton; D. Soulières; S. Janke; J. Dionne; J. Powe 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 165 KB

A phase II study of irinotecan plus chro

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

✍ Garufi, C; Bria, E; Vanni, B; Zappalà, A M R; Sperduti, I; Terzoli, E 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 117 KB

A phase I study of ZD0473 and docetaxel

A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 131)

✍ K.A. Gelmon; D. Stewart; D. Ayers; D. Fry; L. Douglas; L.W. McIntosh; L.K. Seymo 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 172 KB